An antibody that protects against respiratory syncytial virus (RSV) works well for one year but possibly not beyond, according to newly published research.
Nirsevimab, the antibody, “may not be effective after 12 months of administration,” Japanese researchers reported in the study, which was published on Nov. 6 by the Journal of Infection.
